Fund managers back market darling Telix Pharmaceuticals

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 21 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 90%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

A bevvy of healthcare analysts and Australian equities managers have profited from buying fast-rising oncology business Telix, after it unveiled strong sales.

Shares in Telix Pharmaceuticals have surged more than tenfold in five years as a record June quarter of sales supports phenomenal investor interest in the cancer diagnostic and treatment business.

Antares is among Australian equities managers such as Platinum Asset Management, Perennial Partners, Fidelity, Acorn Capital, and Wilson Asset Management that own Telix shares. “We still think shares have further upside,” said Mr Hamilton. “I think that first [June] quarter of commercial sales in Illucix show it’s a great product. It entered the market and got very good awareness of PSMA imaging.

 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки

tommyr345 still a puppet for asxlongtail Only biotech Tom covers strangely, share price is the same as last time you wrote a puff piece for him 🤡

Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 2. in RU

Россия Последние новости, Россия Последние новости